Challenges and Future Directions in Redo Aortic Valve Reintervention After Transcatheter Aortic Valve Replacement Failure
Circulation: Cardiovascular Interventions · 2023-11 · 16 (11)
DOI: 10.1161/circinterventions.123.012966 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation: Cardiovascular Interventions, 2023-11. Verfasst von Syed Zaid und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX (S.Z.). Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis, Aortic Valve Stenosis, Bioprosthesis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Transcatheter aortic valve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Reintervention for failed transcatheter heart valves will likely increase in the future as younger patients are expected to outlive the initial bioprosthesis. While redo-TAVR has emerged as an attractive and less invasive alternative to surgical explantation (TAVR-explant) to treat transcatheter heart valve failure, it may not be feasible in all patients due to the risk of coronary obstruction and impaired coronary access. Conversely, TAVR-explant can be offered to most patients who are surgical candidates, but the reported outcomes have shown high mortality and morbidity. This review provides the latest evidence, current challenges, and future directions on redo-TAVR and TAVR-explant for transcatheter heart valve failure, to guide aortic valve reintervention and facilitate patients’ lifetime management of aortic stenosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX (S.Z.).
- Cardiothoracic Surgery, Minneapolis Heart Institute, Abbott Northwestern Hospital, MN (V.N.B., M.F.).
- Centre for Heart Valve Innovation and Division of Cardiology, St. Paul's Hospital, University of British Columbia, Vancouver, Canada (J.S.).
- Department of Cardiology, Edith Wolfson Medical Center, Tel-Aviv University, Holon, Israel (U.L.).
- Department of Cardiology, The Heart Center, Rigshospitalet, University of Copenhagen, Denmark (O.D.B.).
- Division of Cardiology, University of Padova, Padova, Italy (G.T.).
ORCID-Profile: Syed Zaid, Uri Landes, Giuseppe Tarantini, Kendra J Grubb, Miho Fukui, Mahesh Madhavan, Michael J Mack, Gilbert H L Tang
Zitieren
APA
Zaid, S., Bapat, V. N., Sathananthan, J., Landes, U., De Backer, O., Tarantini, G., Grubb, K. J., Kaneko, T., Khalique, O. K., Jilaihawi, H., Fukui, M., Madhavan, M., Cangut, B., Harrington, K., Thourani, V. H., Makkar, R. R., Leon, M. B., Mack, M. J., & Tang, G. H. L. (2023). Challenges and Future Directions in Redo Aortic Valve Reintervention After Transcatheter Aortic Valve Replacement Failure. Circulation: Cardiovascular Interventions, 16(11). https://doi.org/10.1161/circinterventions.123.012966
Vancouver
Zaid S, Bapat VN, Sathananthan J, Landes U, De Backer O, Tarantini G, et al. Challenges and Future Directions in Redo Aortic Valve Reintervention After Transcatheter Aortic Valve Replacement Failure. Circulation: Cardiovascular Interventions. 2023;16(11). doi:10.1161/circinterventions.123.012966
BibTeX
@article{Zaid2023,
author = {Zaid, Syed and Bapat, Vinayak N and Sathananthan, Janarthanan and Landes, Uri and De Backer, Ole and Tarantini, Giuseppe and Grubb, Kendra J and Kaneko, Tsuyoshi and Khalique, Omar K and Jilaihawi, Hasan and Fukui, Miho and Madhavan, Mahesh and Cangut, Busra and Harrington, Katherine and Thourani, Vinod H and Makkar, Raj R and Leon, Martin B and Mack, Michael J and Tang, Gilbert H L},
title = {Challenges and Future Directions in Redo Aortic Valve Reintervention After Transcatheter Aortic Valve Replacement Failure},
journal = {Circulation: Cardiovascular Interventions},
year = {2023},
volume = {16},
number = {11},
doi = {10.1161/circinterventions.123.012966}
}
EUVIMED